Citations

Mayo Clinic

Showing 10 of 108551 citations.

Payer Type and Emergency Department Visit Prices
Morey, Jacob , Winters, Richard C. , Schupbach, John , Jones, Derick D. , Morey, Jacob R, Mullan, Aidan F.

JAMA Network Open | March 6, 2024 | Volume: 7 | Issue: 3 | Pages: e241297

10.1001/jamanetworkopen.2024.1297 | PMID 38446484 Get It

This cross-sectional study assesses list prices, cash prices, and negotiated rates for emergency department services.
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis
Midol, Charles , Wiebe, Edgar , Siegert, Elise , Huscher, Dörte , Béhal, Hélène, Matteson, Eric L. , Buttgereit, Frank , Sobanski, Vincent , Buttgereit, Frank , Sobanski, Vincent , Launay, David , Hachulla, É.

Rheumatology | March 6, 2024 | Volume: 64 | Issue: 3 | Pages: 1270-1276

10.1093/rheumatology/keae142 | PMID 38452356 Get It

Abstract Objectives Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc. Methods This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy. Results A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04–1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18–4.16]) and treatment with GC (OR 4.48 [2.42–8.26]) were significantly and independently associated with OP. Conclusion Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.
Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance
DeMarco, Mari L. , Budelier, Melissa M. , Budelier, Melissa M , Algeciras‐Schimnich, Alicia

Alzheimer's & Dementia | March 6, 2024 | Volume: 20 | Issue: 5 | Pages: 3661-3663

10.1002/alz.13762 | PMID 38447004 Get It

Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
Tama, Elif , Fansa, Sima , Añazco, Diego , Hurtado, Maria D. , Ghusn, Wissam , Acosta, Andrés , Faubion, Stephanie S. , Shufelt, Chrisandra

Menopause | March 6, 2024 | Volume: 31 | Issue: 4 | Pages: 266-274

10.1097/gme.0000000000002310 | PMID 38446869 Get It

Abstract Objective To compare weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without menopause hormone therapy (HT) use. Methods Retrospective cohort study of postmenopausal women treated with semaglutide for overweight or obesity for ≥3 months. Endpoints: total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months after semaglutide initiation; and percentage of women achieving ≥5% and ≥10% TBWL and changes in cardiometabolic risk markers (glucose, blood pressure, and lipids) at 12 months. Results There were 16 women on HT and 90 on no-HT; mean age 56 ± 8 vs 59 ± 8 yr, P = 0.2 and mean BMI 36 ± 5 vs 39 ± 8 kg/m2, P = 0.1; respectively. Among women on no-HT, White race, dyslipidemia, and depression were more prevalent. Women on HT had a higher TBWL% at 3, 6, 9, and 12 months: 7 ± 3% vs 5 ± 4%, P = 0.01; 13 ± 6% vs 9 ± 5%, P = 0.01; 15 ± 6% vs 10 ± 6%, P = 0.02; and 16 ± 6% vs 12 ± 8%, P = 0.04; respectively. After adjusting for potential confounders, this association remained significant across time. At 12 months, a greater percentage of women on HT achieved ≥5% and ≥10% TBWL. Both groups experienced an improvement in cardiometabolic risk markers. Conclusion In postmenopausal women with overweight or obesity treated with semaglutide, HT use was associated with an improved weight loss response. This association was maintained when adjusted for confounders. Larger studies should be conducted to confirm these results.
Investigating the 2016 surge in firearm violence in Illinois, USA, through community-based organisations: a qualitative study
Dastoor, Jehannaz Dinyar, Thomas, Arielle , Slocum, John D., Regan, Sheila, Stone, Levon, Richardson, Joesph B, Mason, Maryann , Stey, Anne M. , Lin, Katherine, Stey, Anne , Stone, LeVon, Johnson, Julie K. , Lin, Katherine

Injury Prevention | March 6, 2024 | Volume: 30 | Issue: 6 | Pages: 503-508

10.1136/ip-2023-045075 | PMID 38448213 Get It

Background Illinois experienced a historic firearm violence surge in 2016 with a decline to baseline rates in 2018. This study aimed to understand this 2016 surge through the direct accounts of violence prevention community-based organisations (CBOs) in Illinois. Methods We conducted semistructured interviews with 20 representatives from 13 CBOs from the south and west sides of greater Chicago metropolitan area. Interviews were audio recorded, coded and analysed thematically. Results We identified lack of government-derived infrastructure and systemic poverty as the central themes of Illinois’s 2016 firearm violence surge. Participants highlighted the Illinois Budget Impasse halted funding for violence prevention efforts, leading to 2016’s violence. This occurred in the context of a strained relationship with the criminal justice system, where disengagement from police and mistrust in the justice system led victims and families to seek justice outside of the judicial system. Participants emphasised that systemic poverty and the obliteration of community support structures led to overwhelming desperation, which, in turn, increased risky behaviours perceived as necessary for survival. Participants disproportionately identified that this impacted the young people in their communities. Conclusions Lack of government-derived infrastructure and systemic poverty were the central themes of the 2016 firearm violence surge. The insights gained from the 2016 surge are applicable to understanding both current and future surges. CBOs focused on violence prevention offer insights into the context and conditions fuelling surges in the epidemic of violence.
The Relationship Between Anti–SSA-52 and Interstitial Lung Disease
Saunders, Hollie , Baig, Hassan , Li, Yan , White, Launia J. , Hodge, David O. , Lesser, Elizabeth R. , Stowell, Justin T. , Rojas, Carlos A. , Mira‐Avendano, Isabel , Baig, Hassan Z

JCR: Journal of Clinical Rheumatology | March 6, 2024 | Volume: 30 | Issue: 3 | Pages: 101-105

10.1097/rhu.0000000000002064 | PMID 38446195 Get It

Objective The aims of this study were to assess whether a relationship between anti–SSA-52 and interstitial lung disease (ILD) can be further defined, and to enhance screening, detection, and potentially guide treatment. Methods A historical cohort study of 201 patients was conducted at a single tertiary care center between January 1, 2016 and December 31, 2020. All included patients were anti–SSA-52 antibody positive. Chart review was performed for laboratory values, symptoms, pulmonary function tests, treatment, and imaging. Chest computed tomographies were reviewed by chest radiologists. Results Among anti–SSA-52 antibody–positive patients, ILD was found in 125 (62.2%) compared with 76 (37.8%) with no ILD (p = 0.001). For those with ILD, 78 (62.4%) were diagnosed with connective tissue disease (CTD)–associated ILD, 28 (22.4%) were diagnosed ILD only, and 19 (15.2%) met the criteria for interstitial pneumonia with autoimmune features. In patients with CTD-ILD, 18 (23.0%) had their ILD diagnosis made over 6 months before a CTD diagnosis, and an additional 43 (55.1%) had their ILD and CTD diagnosed within 6 months of each other (p < 0.001). Common computed tomography patterns were nonspecific interstitial pneumonia/organizing pneumonia overlap in 44 (35.2%), 25 (20.0%) nonspecific interstitial pneumonia, and 15 (12%) usual interstitial pneumonia. Twenty-eight (35.9%) had antisynthetase syndrome, followed by 16 (20.5%) with dermatomyositis, 10 (12.8%) with CTD overlap, and 6 (7.7%) with systemic scleroderma. Conclusions There was a significant association between anti–SSA-52 antibodies and ILD across a wide spectrum of rheumatological diagnoses. A significant portion of patients were diagnosed with ILD either at the same time or before their CTD diagnosis. Further study will be needed to assess effective treatment and response.
Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit
Khan, Abdul Moiz , Abuali, Inas , Abrams, Hannah R. , Wieduwilt, Matthew J. , Nowakowski, Grzegorz S. , Kumar, Shaji , Larkin, Karilyn , Riaño, Ivy

International Journal of Cancer Care and Delivery | March 6, 2024 | Volume: 4 | Issue: 1 | Pages: No page available

10.53876/001c.94432 Get It

The 2023 Precision Oncology Summit was organized by Binaytara foundation in San Francisco on October 7 th and 8 th . The conference’s theme was the advances in precision oncology and future directions to move away from a one-size-fits-all model to improve outcomes. This manuscript outlines the proceedings of the hematology-focused session during the conference.
Baseline Characteristics and Use of Pretherapeutic 18F-Fluorodeoxyglucose-PET for Pancreatic Cancer
Carlson, Danielle M. , Antwi, Stella K Adjei, Tomlinson, Jennifer L. , Trivedi, Kamaxi H. , Karbhari, Aashna , Patnam, Nandakumar G. , Halfdanarson, Thor R, Goenka, Ajit H. , Truty, Mark J. , Adjei Antwi, Stella K, Trivedi, Kamaxi , Patnam Gopal Chetty, Nandakumar, Patnam, Nandakumar , Tomlinson, Jennifer , Adjei Antwi, Stella Konadu , Carlson, Danielle Marie , Abdelrahman, Amro M.

Journal of the American College of Surgeons | March 6, 2024 | Volume: 239 | Issue: 1 | Pages: 9-17

10.1097/xcs.0000000000001059 | PMID 38445645 Get It

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy. Surgical resection is the only curative modality combined with neoadjuvant chemotherapy to improve survival. Given the limitations of traditional responses such as cross-sectional imaging (CT/MRI) or tumor markers, carbohydrate antigen 19-9 (CA19-9), the 2023 National Comprehensive Cancer Network guidelines included 18F-fluorodeoxyglucose (FDG)-PET as an adjunct to assess response to neoadjuvant chemotherapy. There are common misconceptions on the metabolic activity (tumor avidity) in PDAC so we aimed to describe the baseline characteristics and use of FDG-PET in a cohort of treatment-naive patients with PDAC. STUDY DESIGN: A single-center retrospective study was conducted capturing all biopsy-proven, treatment-naive patients with PDAC who underwent either baseline FDG-PET/CT or FDG-PET/MRI imaging between 2008 and 2023. Baseline FDG-PET characteristics were collected, including primary tumors’ maximum standardized uptake value defined as metabolic activity (FDG uptake) of tumor compared with surrounding pancreatic parenchymal background, and the identification of extrapancreatic metastatic disease. RESULTS: We identified 1,095 treatment-naive patients with PDAC who underwent baseline FDG-PET imaging at diagnosis. CA19-9 was elevated in 76% of patients. Overall, 96.3% (1,054) of patients had FDG-avid tumors with a median maximum standardized uptake value of 6.4. FDG-PET also identified suspicious extrapancreatic metastatic lesions in 50% of patients, with a higher proportion (p < 0.001) in PET/MRI (59.9%) vs PET/CT (44.3%). After controlling for CA19-9 elevation, PET/MRI was superior in detection of extrapancreatic lesions compared with PET/CT. CONCLUSIONS: FDG-PET has significant use in PDAC as a baseline imaging modality earlier neoadjuvant therapy given the majority of tumors are FDG-avid. FDG-PET can identify additional extrapancreatic suspicious lesions allowing for optimal initial staging, with PET/MRI having increased sensitivity over PET/CT.
Comparison of supracondylar radial nerve block and procedural sedation analgesia in the reduction of radius fractures
Kaya, Murtaza , Durusu, Murat, Koca, Kenan, Kılıçkaya, Oğuz

Journal of Emergency Medicine, Trauma & Acute Care | March 6, 2024 | Volume: 2024 | Issue: 3 | Pages: No page available

10.5339/jemtac.2024.10 Get It

Background and Aim: Distal radius fractures are the most frequent upper extremity fractures in the whole population. The incidence of distal radius fractures is 195.2/100,000, and the rate is increasing. It can occur with low-energy trauma in the elderly associated with osteoporosis. The purpose of this study is to compare the two different treatment groups (1. Sedation analgesia, 2. Supracondylar radial nerve block) in terms of reduction in Visual Analogue Scale (VAS) score, the length of hospital stay, complications, side effects, patient-physician satisfaction, and the ease of application. Materials and Methods: Patients diagnosed with distal radius fracture were enrolled prospectively, to whom the study’s exclusion criteria do not apply. The patients included in the study were randomly separated into two groups. Ketofol was administered to the sedation and analgesia group’s patients at a dose of 0.5 mg/kg (ketamine 0.5 mg/kg, propofol 0.5 mg/kg) intravenously, and supracondylar radial nerve block was performed on the other group’s patients under ultrasound guidance. Results: There were 20 patients (6 male, 14 female) in the sedation and analgesia group and 21 patients (11 male, 10 female) in the supracondylar radial nerve block group. There was no significant difference between the groups regarding patient-physician satisfaction and complications. The length of hospital stay was significantly shorter in the supracondylar radial nerve block group (49.25 ± 4.05) compared with the sedation and analgesia group (125 ± 5.85) (p < 0.01). The mean reduction VAS score in the block group was observed to be lower than the admission VAS score (p < 0.01). Conclusion: Consequently, ultrasound-guided supracondylar radial nerve block would be a valuable alternative to procedural sedation analgesia and could become routine clinical practice in treating distal radius fractures.
Optimal systemic therapy in men with low-volume prostate cancer
Saxena, Akshat , Andrews, Jack R. , Bryce, Alan H. , Andrews, Jack, Bryce, Alan H , Riaz, Irbaz Bin

Current Opinion in Urology | March 6, 2024 | Volume: 34 | Issue: 3 | Pages: 183-197

10.1097/mou.0000000000001165 | PMID 38445371 Get It

Purpose of review Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact of advanced imaging modalities, particularly prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, on refining patient subgroups and treatment strategies for patients with low-volume prostate cancer. Recent findings Recent investigations have attempted to redefine low-volume disease, incorporating factors beyond metastatic burden. Advanced imaging, especially PSMA PET, offers enhanced accuracy in detecting metastases, potentially challenging the conventional definition of low volume. The prognosis and treatment of low-volume prostate cancer may vary by the timing of metastatic presentation. Biomarker-directed consolidative therapy, metastases-directed therapy, and de-escalation of systemic therapies will be increasingly important, especially in patients with metachronous low-volume disease. Summary In the absence of validated biomarkers, the management of low-volume prostate cancer as defined by CHAARTED criteria may be guided by the timing of metastatic presentation. For metachronous low-volume disease, we recommend novel hormonal therapy (NHT) doublets with or without consolidative metastasis-directed therapy (MDT), and for synchronous low-volume disease, NHT doublets with or without consolidative MDT and prostate-directed radiation. Docetaxel triplets may be a reasonable alternative in some patients with synchronous presentation. There is no clear role of docetaxel doublets in patients with low-volume disease. In the future, a small subset of low-volume diseases with oligometastases selected by genomics and advanced imaging like PSMA PET may achieve long-term remission with MDT with no systemic therapy.